ClinicalTrials.gg
WithdrawnNCT01552122Updated Aug 27, 2015

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

A Phase 3 interventional study of Odanacatib and Alendronate in Osteoporosis and Postmenopausal Osteoporosis, sponsored by Merck Sharp & Dohme LLC. Withdrawn. Open to female participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2015-08-27.

Primary conditionOsteoporosis, PostmenopausalRegistry: OsteoporosisReclassifiedWhy we changed it
Registry
Osteoporosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis, Postmenopausal
Why
  1. The study's listed conditions name Osteoporosis, Postmenopausal, a narrower term within Osteoporosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
60 Years and older
Sex
Female
01

Study summary

This study will evaluate the therapeutic effects and safety of odanacatib on bone mineral density in osteoporotic postmenopausal women who were previously treated with alendronate.

02

Conditions studied

  • Osteoporosis
  • Postmenopausal Osteoporosis

Browse trials for

03

In context

Osteoporosis, Postmenopausal Reclassified

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.

Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.

Compared within Osteoporosis, Postmenopausal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoporosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In good general health, and for at least 5 years or more
  • Diagnosed with postmenopausal osteoporosis
  • Currently taking alendronate for at least 3 years or more for the treatment of osteoporosis
  • One hip free of orthopedic hardware (ie, total hip device, hip pin); anatomy is suitable to undergo a dual-emission X-ray absorptiometry (DXA) scan (ie, bone mineral density scan)
  • Agrees to not to use any other medications for the treatment of osteoporosis except those provided to the participant during the study

Exclusion criteria

Exclusion Criteria:

  • Evidence of metabolic bone disorder
  • History of (cancer) for 5 years or less
  • Active thyroid disease that cannot be managed with medication
  • Severe renal insufficiency (kidney disease), myocardial infarction, unstable angina, stroke or revascularization, untreated malabsorption syndrome, and/or osteonecrosis of the jaw, or anticipates undergoing a major dental procedure (e.g. dental extraction or implantation)
  • Use, misuse, abuse, and/or addiction of illicit drugs and/or recent history

(within the last year) of drug or alcohol abuse or dependence

  • Use of estrogen with or without progestin and/or raloxifene (ie, Evista®) or tamoxifen (ie, Nolvadex®, Tamofen®)
  • Use of any oral bisphosphonate therapy other than alendronate; intravenous bisphosphonates (zoledronate, ibandronate, pamidronate); any form of calcitonin other than intranasal; anabolic steroids; and/or Strontium-containing products (ie, Osteovalin™)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Odanacatib

    Drug: Odanacatib · Dietary Supplement: Cholecalciferol (Vitamin D3) · Dietary Supplement: Calcium carbonate · Other: Placebo (alendronate)

  • Active comparator
    Alendronate

    Drug: Alendronate · Other: Placebo (odanacatib) · Dietary Supplement: Cholecalciferol (Vitamin D3) · Dietary Supplement: Calcium carbonate

Interventions

  • Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months

    Also known as: MK-0822

  • Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.

    Also known as: Alendronate Sodium, Fosamax

  • OtherPlacebo (odanacatib)

    One compressed tablet administered orally, once-a-week, for 24 months.

  • Dietary supplementCholecalciferolStudies of CholecalciferolCholecalciferol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.

  • Dietary supplementCalcium carbonate

    Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.

  • OtherPlacebo (alendronate)

    One compressed tablet administered orally, once-a-week, for 24 months.

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Bone Mineral Density (BMD) of the Femoral Neck

    Time frame: Baseline and Month 24

Secondary outcomes

  1. Percent Change from Baseline in BMD of the Lumbar Spine, Total Hip, and Trochanter

    Time frame: Baseline and Month 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2012
First posted
Mar 13, 2012
Start
May 2012
Primary completionEst.
Feb 2015
CompletionEst.
Feb 2015
Last update
Aug 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01552122
Responsible party
Sponsor
First posted
Mar 13, 2012
Start date
May 2012
Primary completion
Feb 2015 (estimated)
Completion
Feb 2015 (estimated)
Last update
Aug 27, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Odanacatib

Start the discussion